一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Calderasib；MK-3475A；Placebo，当前状态为招募中。登记地点显示中国北京、重庆、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Calderasib；MK-3475A；Placebo · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University People's Hospital ( Site 2100) · 北京
- Beijing Cancer hospital ( Site 2106) · 北京
- Peking Union Medical College Hospital ( Site 2105) · 北京
- Chongqing University Three Gorges Hospital ( Site 2138) · 重庆
- The First Affiliated Hospital Of Fujian Medical University ( Site 2123) · 福州
- Fujian Cancer Hospital ( Site 2122) · 福州
- Sun Yat-sen University Cancer Center ( Site 2134) · 广州
- Guangxi Medical University Cancer Hospital ( Site 2115) · 南宁
- Fourth Hospital Of Hebei Medical University ( Site 2107) · 石家庄
- Tongji Hospital Tongji Medical,Science & Technology ( Site 2140) · 武汉
- Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 2139) · 武汉
- Xiangya Hospital Central South University ( Site 2136) · 长沙
- The First Affiliated Hospital of Nanchang University ( Site 2121) · 南昌
- Shanghai Pulmonary Hospital ( Site 2125) · 上海
- Fudan University Shanghai Cancer Center ( Site 2137) · 上海
- Zhongshan Hospital of Fudan University ( Site 2119) · 上海
- West China Hospital, Sichuan University ( Site 2142) · 成都
- The Third Peoples Hospital Of Chengdu ( Site 2141) · 成都
- Sichuan Cancer hospital ( Site 2101) · 成都
- The Affiliated Cancer Hospital of Xinjiang Medical ( Site 2110) · 乌鲁木齐
- Yunnan Province Cancer Hospital ( Site 2131) · 昆明
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 2118) · 杭州
- The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 2103) · 杭州
- Zhejiang Cancer Hospital ( Site 2117) · 杭州
- Ningbo No. 2 Hospital ( Site 2124) · 宁波
公开的入选条件
- * Has a histological/cytological diagnosis of non-small cell lung cancer (NSCLC) with predominantly nonsquamous histology and meets one of the following criteria:
- Has newly diagnosed, treatment-naïve, resectable, clinical Stage IIA-IIIB (N2) NSCLC
- Has completely resected, pathological Stage IIA-IIIB (N2) NSCLC, including those previously treated outside the study with neoadjuvant platinum-doublet chemotherapy plus pembrolizumab or MK-3475A, or those who received adjuvant platinum-doublet chemotherapy.
- * Tumor tissue shows the presence of Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation
- * No more than 12 weeks have elapsed between either the surgery following neoadjuvant treatment or last dose of adjuvant platinum-based chemotherapy and the first dose of investigational adjuvant study intervention.
- * Has no evidence of disease based on postsurgical radiological assessment as documented by contrast-enhanced chest/abdomen computed tomography (or magnetic resonance imaging) within 28 days before randomization
- * Has an Eastern Cooperative Oncology Group performance status of 0 or 1 within 10 days before the first dose of the study intervention
- * Human immunodeficiency virus-infected participants must have well controlled HIV on antiretroviral therapy
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07431827；登记信息更新于 2026-09-14。